Premium
Diphenylcyclopropenone for the treatment of cutaneous in‐transit melanoma metastases – results of a prospective, non‐randomized, single‐centre study
Author(s) -
Read T.,
Webber S.,
Tan J.,
Wagels M.,
Schaider H.,
Soyer H.P.,
Smithers B.M.
Publication year - 2017
Publication title -
journal of the european academy of dermatology and venereology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.655
H-Index - 107
eISSN - 1468-3083
pISSN - 0926-9959
DOI - 10.1111/jdv.14422
Subject(s) - medicine , prospective cohort study , melanoma , stage (stratigraphy) , lesion , randomized controlled trial , dermatology , complete response , disease , surgery , oncology , chemotherapy , paleontology , cancer research , biology
Background Current treatments for in‐transit melanoma ( ITM ) metastases are frequently invasive and do not improve overall survival. Recently, there has been increasing investigation into the use of topical agents. Diphenylcyclopropenone or diphencyprone ( DPCP ) is a novel, topical therapy that has been reported to have immune‐sensitizing properties useful in the treatment of ITM . Objective To assess the clinical outcomes of patients treated within a prospective, non‐randomized, non‐comparative study using DPCP for cutaneous ITM metastases. Methods A review was conducted assessing the outcomes of 58 patients prospectively treated using DPCP . Patients had satellite or in‐transit disease (stage IIIB +), with all lesion morphology types included. The patients were treated through a single, specialized clinic with regular outpatient follow‐up. DPCP was topically applied as an aqueous cream in 0.005–1% concentrations once to twice per week for up to 24–48 h of duration. To assess variables associated with response, a per‐protocol statistical analysis was performed. Results Fifty‐four patients were treated who satisfied eligibility criteria for analysis. The overall response rates were as follows: complete response 22%, partial response 39%, stable disease 24% and progressive disease 15%. The mean time to complete response was 10.5 months, mean duration (disease‐free interval) 12.3 months and recurrence rate in complete responders 41%. Lesion morphology was predictive of clinical benefit with a higher response in epidermotropic disease ( P < 0.05). Conclusions DPCP provided a well‐tolerated, convenient and efficacious treatment for cutaneous ITM metastases. Identifying patterns of response may assist treatment selection and improve patient‐rated outcomes.